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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: Obtaining the suggested glycemic control is the most important achievement in 
order to prevent cardiovascular complications in patients with type 2 diabetes. Monotherapy 
often fails after a period of treatment, so that multiple drugs are needed to achieve effective 
glycemic control. A number of oral glucose lowering drugs is now available such as metformin, 
sulfonylureas, non-sulfonylureas secretagogues (metiglinides derivatives), alpha-glucosidases 
inhibitors, and the newest agent: thiazolidinediones (TZD). The possible associations of oral 
glucose lowering drugs for optimal treatment of type 2 diabetes are brieﬂ  y reviewed. In par-
ticular, the effects of different classes of drugs on cardiovascular risk factors (and particular 
hypertension and dyslipidemia) and well recognized cardiovascular disease markers in type 2 
diabetes are analyzed: in this context TZD appear the more innovative drugs and have been 
shown to play a key role in the management of hypertension, dyslipidemia , inﬂ  ammation 
and endothelial disfunction in diabetic patients. The possible adverse effects derived from the 
association of different drug classes are also considered.
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Introduction
Type 2 diabetes: from lifestyle and diet to pharmacological 
treatment
Type 2 diabetes mellitus is a complex metabolic disorder characterized by a variable 
degree of insulin resistance, impaired insulin secretion and excessive hepatic glucose 
production; all these factors contribute to hyperglycemia. Chronic hyperglycemia 
determines impairment of beta-cells function thus worsening hyperglycemia (glu-
cose toxicity). Moreover, excessive dietary lipid introduction impairs islet function 
(lipotoxicity). In the liver, hyperinsulinemia is no longer able to suppress gluconeo-
genesis, which results in hyperglycemia and decreased glycogen storage by the liver 
in the post-prandial state (Golay 2005). Lifestyle interventions are suggested for all 
diabetic patients and in particular for those who present obesity and insulin-resistance. 
Adequate nutritional advices are essential to achieve recommended levels of fasting 
plasma glucose (FPG), post-prandial plasma glucose (PPG), glycosilated hemoglobin 
(HbA1c), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C) triglycerides (TG), 
blood pressure (BP), and body weight. Regular exercise has been shown to improve 
blood glucose control, reduce cardiovascular (CV) risk factors, contribute to weight 
loss and improve well-being. Actually, insulin-resistance may be modulated by physical 
activity; a regular physical activity reduces blood insulin and triglycerides, increases 
HDL-C and reduces BP. Generally, patients with type 2 diabetes and/or insulin-re-
sistance are advised to exert aerobic activity (ie, an exercise that lasts for at least 30 
minutes at low impact of energy) for 3–4 times a week. Physical exercise improves 
insulin action, contributes to weight loss, and reduces several risk factors for CV 
disease. The association between increased levels of physical activity and a reduced Vascular Health and Risk Management 2006:2(4) 465–475
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occurrence of diabetes’ long-term complications suggests 
that regular physical activity has a protective role (Castaneda 
2003). Moreover, regular aerobic exercise reduces visceral 
fat mass and body weight without decreasing lean body mass 
(De Feo 2006). Since physical activity has been shown to 
protect against the development of type 2 diabetes, physi-
cal training programmes suitable for individuals at risk for 
type 2 diabetes should be incorporated into the medical care 
system to a greater extent. People with diabetes should be 
evaluated in order to reduce the risk of adverse effects that 
may possible occur in subjects with macro and/or micro-
vascular complications during physical exercise. Advice 
all patients not to smoke is another important intervention 
recommended in type 2 diabetes management. In many 
cases the optimal glycemic control is not achieved only 
by changes in lifestyle and the most part of type 2 diabetic 
patients needs a pharmacological treatment (American Dia-
betes Association 2006). Type 2 diabetes is a progressive 
condition that requires combination therapy for optimal 
glycemic control (Turner 1999). When hyperglycemia ap-
pears no longer adequately controlled, addition of a second 
agent with similar or different mechanism of action is rec-
ommended (with the exception of SU and non-SU insulin 
secretagogues). The most common combination regimens 
are SU plus metformin or TZD, SU plus TZD and metfor-
min plus TZD (Inzucchi 2002). Many evidences suggest 
that diabetes is strictly related to vascular dysfunction, 
dyslipidemia, hypertension and at least one of these risk 
factors is present in the most part of type 2 diabetic patients 
at the moment of diagnosis. The need to early detect CV 
dysfunction and risk factors in type 2 diabetic patients in 
primary care has been recently stressed (Petri 2006).
Vascular damage and cardiovascular risk 
in type 2 diabetes
A major cause of the reduction in life expectancy in patients 
with diabetes is CV disease and CV complications. Both 
impaired glucose tolerance and diabetes predispose to CV 
alterations (Schnell 2006).
Type 2 diabetes determines a 2-6-fold increased risk of 
CVD and death. Indeed, the risk of major CV events in type 
2 diabetic patients with no history of coronary heart disease 
(CHD) is equivalent to that observed in non-diabetic subjects 
with CHD. Evidences suggest that inﬂ  ammatory processes 
play an important role in the pathogenesis of atheroscle-
rotic CVD. Thus, markers of inﬂ  ammation and endothelial 
dysfunction may provide additional information helpful to 
stratify patient’s risk of developing CVD and may become 
new targets for treatment. On the other hand, evidence has 
emerged suggesting that inﬂ  ammation is also involved in the 
development of type 2 diabetes. Interventions by lifestyle 
modiﬁ  cation or agents with anti-inﬂ  ammatory properties may 
reduce the risk of both type 2 diabetes and atherosclerosis. In 
this context, drugs exerting anti-inﬂ  ammatory and vascular 
effects have future potential to be useful in prevention of 
CVD in type 2 diabetic patients (Ziegler 2005).
Improving glycemic control 
with combination treatment 
and obtaining positive effects on 
vascular risk in type 2 diabetes 
mellitus
Improving glycemic control in patients with type 2 diabetes 
is recognized to be important for the prevention of both 
microvascular and macrovascular complications, particularly 
when aggressive treatment is initiated at an early stage of 
the disease (Vaag 2006). Evidences suggest that combina-
tion therapy using oral antidiabetic agents with different 
mechanisms of action may be more effective in achieving 
and maintaining target blood glucose levels (Turner 1999) 
(Table 1). Metformin is currently the ﬁ  rst-choice treatment 
in patients with type 2 diabetes and obesity, characterized 
by insulin-resistance. Metformin is a biguanide and its 
mechanism of action has been felt to be due to a decrease 
in glucose production in the liver. Moreover, metformin 
improves glucose uptake in adipose tissue and skeletal 
muscle, peripheral insulin sensitivity and, to some extent, 
glucose absorption; a reduction of free fatty acid concentra-
Table 1 The major compounds for treatment of type 2 diabetes 
mellitus
Available glucose lowering drugs
Sulphonylureas: glibenclamide, glipizide, glipizide GITS, glimepiride
Increase insulin secretion
Reduction in HbA1c 1,5–2%
Nonsulphonylureas insulin secretagogues: repaglinide, nateglinide
Increase insulin secretion
Reduction in HbA1c 0,7–1,3%
Biguanides : Metformin
Decrease hepatic glucose production + increase peripheral uptake
Reduction in HbA1c 1,8%
Alpha-glucosidase inhibitors: acarbose , miglitol
Decrease intestinal carbohydrates absorption
Reduction in HbA1c 0,8%
Thiazolidinediones: rosiglitazone, pioglitazone
Adipose (muscle, liver)
Reduction in HbA1c 1,5%Vascular Health and Risk Management 2006:2(4) 465–475
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Combination treatment for type 2 diabetes
tion in the blood has been observed too and is thought to 
be related to a reduction in hepatic gluconeogenesis during 
treatment with biguanides. (Krentz 2005).
Metformin provides reduction of body weight and ame-
liorates lipid abnormalities in obese and non-obese patients: 
moreover, metformin is effective in reducing C reactive 
protein (PCR) and lipoprotein a (Lp(a)) in thus improving, 
at the same time, endothelial dysfunction (Hundal 2003). 
If metformin is not tolerated or contraindicated, the second 
choice is represented by a thiazolidinedione TZD or a sulfo-
nylurea (SU). Sulfonylureas are efﬁ  cacious and particularly 
useful in type 2 diabetic patients who present primarily 
insulin secretion deﬁ  ciency and, in association with insulin 
sensitizing drugs (metformin and TZD), in those patients with 
type 2 diabetes mellitus who do not achieve recommended 
glycemic control (Derosa 2007).
Acarbose and miglitol, two disaccharidase inhibitors, 
are effective in combination with SU, even if metformin 
and insulin in association to SUs seem to be more effective 
and safe providing a decrease of glycosilated haemoglobin 
about twice as great as that obtained with acarbose plus SUs 
(Rendell 2004). Anyway, evidences are available concerning 
with a potential risk of cardiovascular mortality in subjects 
treated with metformin in association with SUs (Evans 
2006). In the UKPDS a signiﬁ  cant increase in mortality was 
observed in those patients in whom metformin was added to 
initial SU treatment. Other evidences point out a potential 
risk in adding metformin to SUs therapy in patients with 
CHD. A theoretical cardiac risk for ﬁ  rst generation SU has 
been observed. Newest sulfonylureas, glimepiride, gliclazide 
and glipizide have lower afﬁ  nity for cardiac SUR-receptors 
and, in animal models, glimepiride seems ineffective in 
reducing the protective effect of ischemic preconditioning 
(Riveline 2003).
Metiglinides derivatives (repaglinide and nateglinide) 
are a class of insulin secretagogues acting increasing in-
sulin secretion by activating the same or similar receptors 
activated by SUs. Repaglinide is the available drug in the 
market and presents some advantages vs other SUs, the 
most important being a reduced risk of hypoglycemia. 
Repaglinide is effective in combination treatment with 
TZD or metformin, and seems to be useful in association 
with a single daily administration of insulin (Rendell 2004). 
The peroxisome proliferator-activated receptors (PPARs) 
are part of a nuclear receptor superfamily which plays a 
fundamental role in cell metabolism, particularly in rela-
tion to adipogenesis, lipid metabolism and peripheral tissue 
insulin-sensitivity.
Thiazolidinediones are PPARγ agonists that improve 
insulin-sensitivity by complex mechanisms. The thiazolidin-
ediones currently available for treatment of type 2 diabetes 
are pioglitazone and rosiglitazone while troglitazone has 
been withdrawn due to the report of many cases of hepatic 
toxicity. Efﬁ  cacy and safety of pioglitazone and rosiglitazone 
as antidiabetic drugs has been well established in a number 
of clinical studies. Increasing interest is now focused on the 
range of pleiotropic effects of TZD (Roberts 2003).
In non-diabetic patients with CV risk factors, pioglitazone 
treatment enhances insulin sensitivity, decreases PCR, and 
improves endothelial vasodilator function. These effects do 
not appear to be closely related to improvement in glycemic 
control, suggesting that pioglitazone may have beneﬁ  cial 
vascular properties independent of its effect on insulin sen-
sitivity and inﬂ  ammation (Campia 2006).
Association of metformin and rosiglitazone is effective 
in reducing factors related to an increased CV risk in patients 
with type 2 diabetes end/or insulin-resistance. In 90 patients 
treated with the association of metformin and rosiglitazone 
for 24 weeks, matrix metalloproteinase-9 (MMP-9) levels 
and plasminogen activator inhibitor type 1 (PAI-1) levels 
have been decreased by 14% and 33% with the contemporary 
administration of rosiglitazone (8 mg/day) and metformin 
(1000 mg/day) vs an increase in MMP-9 levels of 22% and 
a reduction in PAI-I levels of 0.6% with only metformin at a 
dosage of 2000 mg/day (Weissman 2004). In an other study, 
treatment with rosiglitazone (4 mg/day) and metformin (2000 
mg/day), contemporary administered to 95 type 2 diabetic 
patients, has determined, after 12 months, a greater signiﬁ  cant 
reduction of PAI-1 levels (26.6%, p < 0.01) vs treatment with 
glimepiride in association with metformin (Derosa 2005 a).
Fixed dose combination of rosiglitazone and metformin 
is now available in the market (Avandamet, Glaxo Smith 
Klein) while a ﬁ  xed dose combination of metformin and 
pioglitazone has been undergoing analysis since 2004 
(Campbell 2005).
Addition of rosiglitazone to sulfonylurea has been shown 
to improve glycemic control in patients with type 2 diabetes 
previously treated with sulfonylurea monotherapy and pro-
duced a positive effect on insulin resistance, beta-cell func-
tion, CV risk markers, and adiponectin, thus supporting the 
rationale of combining rosiglitazone with sulfonylurea drugs 
in patients with type 2 diabetes (Pfuntzer 2006). A combined 
ﬁ  xed dose of rosiglitazone plus glimepirirde has been recently 
approved (Avandaryl, Glaxo Smith Klein).
Hypertension is one of the most frequent conditions 
associated with type 2 diabetes, and represents one of the Vascular Health and Risk Management 2006:2(4) 465–475
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major causes of stroke in diabetic patients. Moreover, 
antihyperglycemic drugs might have a small, but clinically 
signiﬁ  cant, beneﬁ  cial effect on BP in patients with diabetes 
mellitus. In a 12-month study, combination treatment with 
rosiglitazone and metformin, but not glimepiride and met-
formin, was associated with a signiﬁ  cant improvement in BP 
control (Derosa 2005b).
Another well established CV risk factor frequently affect-
ing type 2 diabetic patients is dyslipidemia. Combination of 
glimepiride and pioglitazone in subjects with type 2 diabetes 
mellitus and metabolic syndrome, who had not previously 
achieved adequate glycemic control with sulfonylurea or 
metformin or had undergone adverse effects, has demon-
strated to be signiﬁ  cantly more effective in improving lipid 
abnormalities (Derosa 2004).
Insulin-resistance is associated to elevated concentrations of 
plasmatic ﬁ  brinogen, increased blood viscosity and platelet acti-
vation and aggregation. Plasminogen activator inhibitor – type 1 
(PAI-1) is a potent inhibitor of ﬁ  brynolisis and its concentration 
is directly related to hyperinsulinemia (Jokl 1994).
Beyond glycemic control, association of metformin plus 
TZDs sems to be effective in reducing different markers of 
CV risk factors as PAI-I levels, platelet aggregation and 
expression of a number of molecules which provide adhesion 
to chronic inﬂ  ammation markers (Bailey 2005). The addi-
tion of a thiazolinedione to glimepiride treatment in type 2 
diabetic subjects with the metabolic syndrome determines a 
slight but signiﬁ  cant reduction of PAI-1 values, related to a 
similar reduction in insulin resistance (Derosa 2005c).
Pioglitazone plus metformin administered for 8 weeks in 
a group of patients with type 2 diabetes mellitus and hyper-
tension has been shown to reduce signiﬁ  cantly both mean 
systolic and diastolic BP during the night independently of 
the reduction of glycemia (Negro 2004).
Like almost all secretagogues, glimepiride can determine 
increase in body weight. Anyway, glimepiride has shown 
to reduce weight gain when a combination treatment of 
insulin NPH and glimepiride was compared with an insulin 
regimen. Rosiglitazone might determine ﬂ  uid retention and 
exacerbate heart failure in type 2 diabetic patients and is not 
recommended for patients in NYHA class 2–4 heart failure. 
Screening underlying cardiac disease in patients as well as the 
use of drugs related with the development of ﬂ  uid retention of 
pedal edema is recommended before starting therapy with a 
TZD associated with a SU (Nesto 2004). Thiazolidinediones 
has demonstrated to induce weight gain in type 2 diabetic 
patients. The weight gain appears to be related to the dose. 
Rosiglitazone/glimepiride combination therapy is affected 
by weight gain more then rosiglitazone or sulfonylurea 
administered as monotherapy (Hussein 2004).
Weight loss following a low calories diet is associated 
with a decrease in PPAR-γ expression in subcutaneous adi-
pose tissue, related with the differentiation of adipocytes. 
Experts suggest a program of nutritional education and 
exercise at prescription, with restriction in calories intake in 
particular in those patients at high risk of weight gain (Fon-
seca 2003). Moreover, the association of thiazolidinediones 
and diuretics seems to be a possible choice to reduce edema 
during treatment and must be considered when a combination 
of a TZD and a SU appears to be the best treatment to obtain 
the optimal control of type 2 diabetes (Mudaliar 2003).
The use of insulin in association with oral hypoglycemic 
drugs has been encouraged in the last ﬁ  ve years. In particu-
lar, the incoming of insulin glargine has reduced the risk 
of hypoglycemia which limited the association of a long 
acting insulin (like NPH) with secretagogues, like SUs and 
repaglinide
Metformin therapy in association with insulin (regular 
or long acting insulins like glargine and NPH) is a success-
ful strategy in patients who need to contain body weight 
increase, but have not obtained the recommended goals with 
metformin alone (Rendell 2004) (Table 2).
Conclusions
Excellent glycemic control does not impact non tradi-
tional risk factors for CVD equally, but various diabetes 
Table 2 Approved FDA association
Compound FDA  approved  association
Metformin Monotherapy
 Sulfonylureas
 Non-sulfonylureas
 Alpha-glucosidase  inhibitors
 Thiazolidinediones
 Insulin
Sulfonylurea Monotherapy
 Metformin
 Thiazolidinediones
 Alpha-glucosidase  inhibitors
 Insulin
Non-sulfonylureas Monotherapy
 Metformin
Alpha-glucosidase Monotherapy
 inhibitors Sulfonylureas
 Metformin
 Insulin
 Monotherapy
 Sulfonylureas
Thiazolidinediones Metformin
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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Combination treatment for type 2 diabetes
Box 1 Cardiovascular effects of drugs in monotherapy
Monotherapy
Metformin: demonstrated signiﬁ  cant decrease in myocardial infarction 
incidence and in prevention of cardiovascular complications of type 2 
diabetes; it reduces PCR and Lp(a) (Hundal and Inzucchi 2003).
Rosiglitazone: demonstrated signiﬁ  cant improvement of systolic and 
diastolic blood pressure:
Controversial impact on lipid abnormalities. In clinical trials has demon-
strated to have a neutral-worsening on lipoproteins.
Pioglitazone: improves lipid abnormalities. Demonstrated to reduce 
intima-media thickness with a good impact on endothelium disfunction.
Pioglitazone and rosiglitazone: reduce vascular inﬂ  ammation, stimulate 
ﬁ  brynolisis; decrease the production of adhesion molecules and metal-
loproteinases; (Verges 2004): decreases liver fat and increases insulin 
clearance (Tiikkainen et al 2004).
Sulphonylureas: may reduce heart “preconditioning” so that are not 
considered completely safe in patients with previous myocardial infarc-
tion. New generation sulfonylureas (glimepiride) is considered safer than 
others because it is more selective.
medications have different effects on these risk factors. These 
ﬁ  ndings may be useful for appropriate therapeutic choices 
for patients with type 2 diabetes, although larger studies with 
more appropriate treatment comparisons may be necessary. 
Increasing comprehension of the complex pathogeneses of 
type 2 diabetes, and related CVD, determines the awareness 
that systematic application of a scheme in treating type 2 
diabetic patients is no longer the adequate approach.
Even if not formally approved by the FDA, triple therapy 
is common in clinical practice and experimental results dem-
onstrate the possibility to obtain better glycemic control and 
effectiveness on other recognized CV risk factors. Anyway, the 
fear of adverse events is usually the cause of discontinuation 
of multiple therapies by patients and physicians too. Increasing 
evidences suggest that an individualized therapeutic scheme 
with oral glucose lowering agents in combination and in com-
bination with insulin may be successful and may be affected by 
loss side effects, such as weight gain, which commonly occur 
with more accepted monotherapy as sulfonylureas.
Of the currently available agents, metformin and thia-
zolidinediones seem to be the most effective drugs in CV 
protection. Metformin has a positive effect on several CV 
risk factors and has been shown to reduce cardiac events in 
overweight subjects with type 2 diabetes. Thiazolidinediones 
favorably modulate a large spectrum of conventional and 
non-conventional CV risk factors. Rosiglitazone and piogli-
tazone possess beneﬁ  cial effects on other cardiovascular risk 
factors associated with the insulin resistance syndrome. Thus, 
these agents were shown to decrease blood pressure, enhance 
myocardial function and ﬁ  brinolysis, as well as possess anti-
inﬂ  ammatory and other beneﬁ  cial vascular effects.
Sulfonylureas have beneﬁ  cial effects on some risk factors 
but outcome studies have failed to show a reduction these 
agents. At present, clinical management of insulin-resistant 
type 2diabetes should be based on metformin, with the ad-
dition of thiazolidinediones and sulfonylureas to achieve 
optimal glycemic control.
In conclusion optimizing combination treatment represent 
the real strategy to successfully obtain longer control of type 
2 diabetes, but, to date, stepwise approach is preferred and 
combination therapy as initial approach not recommended.
The real challenge is now to obtain goal standards not 
only in glycemic control but also in the magnitude of mecha-
nisms that underlie early onset of macro and microvascualr 
complications in type 2 diabetes. Newer agents, such as thia-
zolidinediones in combination with old, well experimented 
ones, such as sulfonylureas and metformin, are promising in 
this context (see Boxes 1, 2, 3, and 4). Boxes 1, 2, 3 and 4 
illustrate some interesting results obtained in recent clinical 
studies; even many of these studies were not powered for 
Box 2 Metformin + sulfonylureas
Association Cardiovascular  risk 
   with  association
    Increase in cardiovascular mortality
Metformin  Glibenclamide in association with    
 
+
  metformin therapy seems to present  
   special  risk
Sulfonylureas  Metformin + Glimepiride: reduce    
    non tradional cardiovascular risk factors
    (Lp(a) levels and homocisteinemia)   
    (Derosa et al 2005)
Box 3 Thiazolidinediones + sulfonylureas
Association  Cardiovascular risk with    
 association
  Rosiglitazone + Glimepiride:    
  Improvement in long-term blood pres 
 sure  control
  (Derosa et al 2005)
  Rosiglitazone or Pioglitazone +   
 Glimepiride: signiﬁ  cant decrease
  in PAI-1 levels (Derosa et al 2005)
Thiazolidinediones  Pioglitazone + Sulfonylureas:    
    reduction of the urinary albumin-to-
  +  creatinine ratio, signiﬁ  cant rise in LDL  
  cholesterol,  and  signiﬁ  cant
Sulfonylureas  Improvements in triglyceride levels and  
    HDL cholesterol levels (Hanefeld et al
  2004)
  Pioglitazone  +  Glimepiride: 
    improvement in high-sensitivity C-reactive
    protein levels (Pfuntzer et al 2006)Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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the noted endpoints, the boxes are intended to be stimulating 
starting points for further research.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Association 2003). Such index exceeds not only the number of deaths in men, but also the
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disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
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